HCW Biologics (HCWB) vs Silexion Therapeutics (SLXN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
HCW Biologics is the larger company by market cap ($3.6 million vs $3.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCWB | SLXN |
|---|---|---|
| Share price | $1.60 | $0.2146 |
| Market cap | $3.58M | $3.11M |
| 1-day change | +4.58% | -8.64% |
| EPS (TTM) | $-19.84 | $-24.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.30 | $39.40 |
| 52-week low | $1.50 | $0.2079 |
| Distance from 52-week high | -94.14% | -99.46% |
| Analyst consensus | buy | none |
| Avg. price target upside | +2900.00% | +2229.92% |
| Average volume | 381.72K | 10.05M |
| Shares outstanding | 2.24M | 14.47M |
| Employees | 35 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Silexion Therapeutics
SLXN stock →Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 13 employees
HCWB vs SLXN FAQ
Which is bigger, HCW Biologics or Silexion Therapeutics?
HCW Biologics (HCWB) is larger, with a market capitalization of $3.58M compared with $3.11M for Silexion Therapeutics (SLXN).
Are HCW Biologics and Silexion Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for HCW Biologics and Biotechnology: Biological Products (No Diagnostic Substances) for Silexion Therapeutics.